Topiramate

— Landmark European approval will grant young patients and families an evidence-based therapy alongside lifestyle interventions AMSTERDAM, Oct. 19, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs and life-limiting diseases, today announced the positive conclusion of the European variation procedure to extend the indication of QSIVA ® (phentermine/topiramate MR) to adolescents aged 12 years and older with obesity. The national medicines agencies of the 17 countries in the procedure will now issue national decisions, expected in as little as 30 days. QSIVA ® is already approved in these countries for weight management in adults: Croatia, Czechia, Denmark, Finland, Greece * , Hungary, Iceland, Ireland, Lithuania, Malta, Norway, Poland, Portugal, Romania, Slovakia, Slovenia and Sweden. "Adolescent obesity represents one of the most pressing public health challenges in Europe today," said John Amos, Chief Executive Officer at VIVUS LLC. "Securing broader access for QSIVA ® allows us to bridge a significant gap in pediatric care, offering clinicians and families an evidence-based treatment option when lifestyle changes alone aren't enough." The positive outcome of the variation procedure was based on results from a 2022 study , a double-blind, placebo-controlled, clinical trial that evaluated the safety and efficacy of phentermine/topiramate MR over a 56-week period in 223 adolescents with obesity. "Treating obesity early in life is critical to breaking a cycle that can cause severe, lifelong health issues," said Santosh T. Varghese, MD, President at VIVUS Global Pharmaceutical Development and Chief Medical Officer at VIVUS LLC. "With broader European access to QSIVA ® , healthcare providers will have a therapeutic tool to help adolescents manage weight alongside diet and exercise before long-term complications set in." Globally, obesity and overweight pose significant public health challenges, impacting millions of people across Europe. These conditions increase the risk of various health problems, such as heart disease and autoimmune diseases, such as multiple sclerosis, Crohn’s disease, arthritis, and type 1 diabetes. VIVUS markets its phentermine/topiramate extended-release therapy under the brand name QSYMIA ® in the United States, Greece, and the Middle East and North Africa (MENA) region, and under the brand name QSIVA ® , the European brand name for QSYMIA ® , in approved countries across Europe. QSYMIA has been available in the United States since 2012, and its indication was extended to adolescents aged 12 years and older on June 27, 2022. In March 2025, VIVUS launched QSYMIA ® in the United Arab Emirates for adults and pediatric patients aged 12 and older, marking the company’s entry into the MENA region. QSIVA ® is already approved for adults in 17 European countries, and will now be extended to adolescents in these same countries following national approvals. For more information about QSIVA, please visit About VIVUS VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about the Company, please visit . About QSIVA ® QSIVA ® (phentermine/topiramate MR) (the European brand name for QSYMIA ® ) is approved in Croatia, Czechia, Denmark, Finland, Greece, Hungary, Iceland, Ireland, Lithuania, Malta, Norway, Poland, Portugal, Romania, Slovakia, Slovenia and Sweden. QSIVA ® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. The effect of QSIVA ® on reducing cardiovascular morbidity and mortality has not been established. The safety and effectiveness of QSIVA ® in combination with other products intended for weight loss, including prescription and over-the-counter drugs and herbal preparations, have not been established. For more information on QSIVA ® , please visit The website is accessible for healthcare professionals only through registration. Important Safety Information QSIVA ® (phentermine/topiramate MR) is contraindicated in pregnancy and in women of childbearing potential not using highly effective contraception, as topiramate can cause major congenital malformations. Do not use QSIVA ® in patients with glaucoma, hyperthyroidism, or MAOI use. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity, has been reported in patients taking topiramate, an ingredient in QSIVA ® . QSIVA ® may cause increased heart rate, mood changes, and cognitive disturbances; caution is advised when driving. Common adverse reactions include paraesthesia, dizziness, altered taste, insomnia, constipation, and dry mouth. Forward-Looking Statements Important Information and Cautionary Note Regarding Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and/or covered by the "Bespeaks Caution" doctrine applied by the courts under the antifraud provisions of the federal securities laws, and other applicable provisions of the federal securities laws. Such forward-looking statements are based on current expectations, management's beliefs, and certain assumptions made by the Company's management. These statements may be identified by the use of forward-looking words such as "will," "shall," "may," "believe," "expect," "forecast," "intend," "anticipate," "predict," "should," "plan," "likely," "opportunity," "estimated," and "potential," and/or the negative use of these words or other similar words. All forward-looking statements included in this document are based on the Company's current expectations, and the Company assumes no obligation to update any such forward-looking statements except to the extent otherwise required by law. Forward-looking information about QSIVA, including statements regarding the expected extension of its indication to adolescents aged 12 years and older, the timing and outcome of national decisions in the 17 countries in the procedure, its clinical efficacy and safety pro adolescents, and its role in long-term obesity management, involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied in this press release. Risks related to QSIVA include whether, and when, the national medicines agencies in each country will issue decisions extending the indication to adolescents; the final wording of the adolescent indication, warnings and other labeling agreed in each country; conditions of use in adolescents, including the requirements of the topiramate pregnancy prevention program for adolescents of childbearing potential; whether, and when, pricing and reimbursement will be obtained for adolescent use in each country; acceptance of QSIVA by pediatric and other prescribers, patients and families; new safety findings or adverse events in the adolescent population, including from post-authorization commitments; competitive developments in the weight management market including injectable medications and other treatments approved for adolescents, and whether QSIVA will continue to be commercially successful in approved markets. General risks include the ability to successfully manage commercial programs across multiple international markets; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of QSIVA; supply chain challenges; and competitive developments in the obesity and weight management therapeutic area. The above factors, risks, and uncertainties are difficult to predict, contain uncertainties that may materially affect actual results, and may be beyond the Company's control. New factors, risks, and uncertainties emerge from time to time, and it is not possible for management to predict all such factors, risks, and uncertainties. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore any of these statements may prove to be inaccurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by the Company or any other person that the Company's objectives and plans will be achieved. These forward-looking statements speak only as of the date such statements were made or any earlier date indicated, and the Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in underlying assumptions, or otherwise, unless otherwise required by law. This announcement is made in accordance with applicable securities regulations including the EU Market Abuse Regulation. This press release is intended for the European market only. Contacts VIVUS BV T: +31 20 262 0959 Media – FINN Partners Julian Tyndale-Biscoe julian.tyndale-biscoe@finnpartners.com T: +44 20 7046 8280 * VIVUS markets its phentermine/topiramate extended-release therapy under the brand name QSYMIA® in the United States, Greece, and the Middle East and North Africa (MENA) region.

— Establishes QSYMIA as one of the most affordable branded weight-management options available in the United States — Effective immediately, uniform pricing across all four doses lowers QSYMIA’s annual cost to $780 to $900, or roughly $2.50 per day — Patients can access new pricing at retail locations, including Costco and GoodRx, or through home delivery via QSYMIA Engage CAMPBELL, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focuses on advancing treatments for patients with serious unmet medical needs, today announced that patients with a valid prescription can now receive a 30-day supply of QSYMIA® (phentermine and topiramate extended-release capsules) CIV for $75 or less – about $2.50 per day or less. Effective immediately across all four doses, the new pricing brings QSYMIA’s annual cost down to $780 to $900, establishing it as one of the most affordable branded weight-management options on the market. Patients can access new pricing at Costco, at participating pharmacies with GoodRx, or through home delivery via Qsymia Engage. The cash price is the same across all four QSYMIA dose strengths - 3.75 mg/23 mg, 7.5 mg/46 mg, 11.25 mg/69 mg and 15 mg/92 mg– ensuring patients pay the exact same rate even as the dose increases. Costco members pay $65 per 30-day supply (about $2.17 a day) for in-store pickup, or $65 plus a $2.99 shipping charge for Costco home delivery. Qsymia Engage home delivery is $74.99 per 30-day supply (about $2.50 a day); and GoodRx offers a $75 price (about $2.50 a day) at participating retail pharmacies when patients present a GoodRx coupon at checkout. Additional discount pricing is available for 90-day prescriptions through Qsymia Engage home delivery. For patients filling 12 30-day prescriptions, the annual drug cost is $780 through Costco (about $2.14 a day), $899.88 through Qsymia Engage or $900 with GoodRx (about $2.46 to $2.47 a day). Costco home delivery totals $815.88 annually, including 12 monthly $2.99 shipping charges. "Obesity care requires long-term commitment, and financial strain should not force patients to compromise on their treatment,” said John Amos, Chief Executive Officer of VIVUS LLC. “At $2.50 a day or less, QSYMIA sets a new benchmark for affordability in branded weight management. With an annual cost of $780 to $900 across all four dosage strengths, QSYMIA delivers the lowest out-of-pocket price point of any branded option on the market today. Whether starting on the lowest dose or titrating to the highest, patients receive guaranteed price protection, giving them an unmatched combination of proven efficacy and out-of-pocket savings." QSYMIA is a once-daily capsule, taken each morning with or without food. In the pivotal EQUIP and CONQUER trials, patients taking the top dose (15 mg/92 mg) lost an average of 9.8% to 10.9% of body weight at one year, compared with 1.2% to 1.6% with placebo. In a post-hoc analysis of those combined studies (922 adult patients completing 56 weeks of treatment on the top dose), 1 in 5 adult patients (N=200) achieved 20% weight loss, averaging 60 pounds lost and 9 inches of waist reduction, on QSYMIA's top dose. Cash-pay context across weight-management medicines Published manufacturer cash programs show a wide affordability range across oral and injectable weight-management medicines. As of August 22, 2026, injectable GLP-1 cash programs offered by Novo Nordisk and Eli Lilly were publicly listed from about $199 introductory pricing to $449 a month - roughly $2,388 to $5,388 a year, or about $6.55 to $14.75 a day - with some programs pricing higher at higher doses. Oral GLP-1 pills, also offered by Novo Nordisk and Eli Lilly, were publicly listed from about $149 to $349 a month - roughly $1,788 to $4,188 a year, or about $4.90 to $11.63 a day - depending on dose. Other, non-injectable weight-management cash programs were publicly listed from about $99 to $299 a month, or roughly $1,188 to $3,588 a year. Qsymia remains $780 to $900 a year, or $2.50 a day or less, across all four doses - a fraction of the injectable or oral GLP-1 cash price from either manufacturer. Prices are publicly listed cash-program amounts - not wholesale acquisition cost, estimated net price or insured out-of-pocket cost - and may change. Eligibility, introductory offers, dose, refill timing and other restrictions apply. Products differ in indication, efficacy, dosing, safety, contraindications and access. This price-only snapshot is not a head-to-head comparison of clinical performance, safety, value or total treatment cost. About VIVUS VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about the Company, please visit http://www.vivus.com. About QSYMIA QSYMIA is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. The effect of QSYMIA on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of QSYMIA in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. For more information on QSYMIA, please visit https://QSYMIA.com/. Important Safety Information QSYMIA is a schedule IV controlled-substance medication for adults and children 12 years and older to help with weight loss when combined with diet and exercise. WARNING: Do not take Qsymia if you are pregnant or trying to become pregnant, as it can cause serious birth defects; topiramate may cause suicidal thoughts. Do not take Qsymia if you have glaucoma, an overactive thyroid, or take MAOIs. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity, has been reported in patients taking topiramate, an ingredient in QSYMIA. Common side effects include tingling in the hands and feet, dizziness, altered taste, dry mouth, constipation, and trouble sleeping. Report side effects to VIVUS LLC at 1-888-998-4887 or FDA at 1-800-FDA-1088. Pricing terms The stated Qsymia prices apply equally to all four dose strengths. The $75 GoodRx price requires patients to present a valid GoodRx coupon (available at GoodRx.com or in the GoodRx app) at a participating retail pharmacy; it is not an automatic discount. Full pricing terms, channel eligibility, shipping charges, 90-day discount pricing and other restrictions - including details on Costco, GoodRx and Qsymia Engage home delivery - are available at QsymiaEngage.com. Competing cash-pay program figures are drawn from publicly available manufacturer or program pricing pages as of August 22, 2026 and reflect list cash prices only; they exclude manufacturer coupons, insurance, rebates or other adjustments. References to Novo Nordisk and Eli Lilly describe the manufacturers of the cited injectable and oral GLP-1 cash programs generally and do not name specific branded products; Novo Nordisk and Eli Lilly are not affiliated with VIVUS or Qsymia and have not endorsed this comparison. GoodRx is a trademark of GoodRx, Inc. and is not affiliated with VIVUS or Qsymia. Eligibility requirements, geographic restrictions and other terms may apply. VIVUS reserves the right to modify or discontinue the pricing programs at any time without notice. Sources Competitor cash-pay program pricing: publicly available manufacturer and program pricing pages for weight-management medicines, including Novo Nordisk and Eli Lilly injectable GLP-1 cash programs, reviewed as of August 22, 2026. Qsymia Engage pricing: 90-day home-delivery pricing and program terms Qsymia labeling and efficacy data: Qsymia Full Prescribing Information, revised March 2026; Proven Results with Qsymia (data on file, VIVUS LLC). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the availability, terms and duration of QSYMIA pricing programs; anticipated patient access through Costco, GoodRx, Qsymia Engage and other channels; the expected affordability of QSYMIA relative to other weight-management medicines; and the potential benefits of QSYMIA. Words such as “will,” “may,” “believe,” “expect,” “intend,” “anticipate,” “plan,” “potential” and similar expressions identify forward-looking statements. These statements are based on management’s current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially, including: VIVUS’s ability and decision to maintain the announced pricing, which VIVUS may modify or discontinue at any time; decisions by Costco, GoodRx, participating pharmacies and other partners to continue offering the pricing; patient and prescriber awareness and adoption; the financial impact of reduced pricing on VIVUS’s revenue and margins; pricing actions by other manufacturers, which may cause the comparisons in this release to become outdated; changes in insurance coverage, reimbursement and government pricing programs for weight-management medicines; manufacturing, supply chain or distribution disruptions; regulatory actions affecting QSYMIA’s labeling, REMS, marketing or availability; legal or regulatory scrutiny of pricing, discount or direct-to-patient programs; new safety or efficacy information; and competitive developments in the treatment of obesity. New risks emerge from time to time, and VIVUS cannot predict all of them. Forward-looking statements speak only as of the date of this release, and VIVUS undertakes no obligation to update or revise them, whether as a result of new information, future events or otherwise, except as required by law. Media ContactVIVUS LLC1-650-934-5200 Media – FINN PartnersGlenn SilverGlenn.Silver@finnpartners.comT: +1 973-818-8198